Close Menu

NEW YORK (GenomeWeb) – The US Centers for Medicare & Medicaid Services on Friday reined in a national coverage proposal for next-generation sequencing oncology panels that had the lab industry worried that they'd have to successfully take their tests through US Food and Drug Administration's review if they hoped to secure Medicare coverage and had cancer patients vexed that the government payor was limiting their access to precision medicine.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.